DBV Technologies Reports Full Year 2025 Financial Results and Business Update
View original at globenewswire.com“Reported cash and cash equivalents of $194 million as of December 31, 2025, plus additional gross proceeds of $94 million received on January 16, 2026”
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
BLA submission for 4-7 year olds anticipated in the first half of 2026 with potential for Priority Review
60% confidenceCash and cash equivalents are sufficient to fund operations into the second quarter of 2027
60% confidenceCompletion of enrollment of COMFORT Toddlers safety study and subsequent topline results readout expected in 2026
60% confidenceOur focus on bringing the VIASKIN Peanut Patch to peanut-allergic children ages 1-7 years remains unwavering
60% confidenceI am pleased with our progress to date in enhancing DBV's capabilities and building a company ready for launch
60% confidenceWe entered 2025 with a clear set of priorities – strengthening our financial position, advancing our clinical development program (including completing VITESSE and initiating COMFORT Toddlers), and preparing for the BLA submission and commercialization of the VIASKIN Peanut Patch in the United States, if approved
60% confidenceBLA submission for 1-3 year olds anticipated in the second half of 2026 under an Accelerated Approval Pathway
60% confidence